Gel formulations for treatment of the ophthalmic complications in cystinosis

International Journal of Pharmaceutics

Volumn 392, Issue 1-2, 2010, Pages 192-197

  Buchan, Barbara ^a   Kay, Graeme ^a   Heneghan, Anne ^a   Matthews, Kerr H ^a   Cairns, Donald ^a  

^a ROBERT GORDON UNIVERSITY   (United Kingdom)

Author keywords

Cystinosis; Gel; Modified release; Ophthalmic delivery

Indexed keywords

CARBOMER; MERCAPTAMINE;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYSTINOSIS; DRUG SOLUBILITY; DRUG STRUCTURE; EYE DISEASE; FLOW KINETICS; HYDROGEL; MEAN RESIDENCE TIME; PH; PRIORITY JOURNAL; SHEAR STRESS;

ACRYLIC RESINS; ADHESIVENESS; ANIMALS; CATTLE; CORNEA; CORNEAL DISEASES; CYSTEAMINE; CYSTINOSIS; DRUG CARRIERS; DRUG COMPOUNDING; GELS; HYDROGEN-ION CONCENTRATION; MOLECULAR STRUCTURE; PHENYLALANINE; RHEOLOGY; SOLUBILITY;

EID: 77952740815     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.065     Document Type: Article

References (41)

1. Ahmed I., Patton T.F. Importance of the noncorneal absorption route in topical opthalminc drug delivery. Invest. Ophthalmol. Vis. Sci. 1985, 26:584-587.
2. Ahmed I., Patton T.F. Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption. Int. J. Pharm. 1987, 38:9-21.
3. Berge S.M., Bighley L.D., Monkhouse D.C. Pharmaceutical salts. J. Pharm. Sci. 1977, 66:1-19.
4. Bothner H., Waaler T., Wik O. Rheological characterisation of tear substitutes. Drug Dev. Ind. Pharm. 1990, 16:615-616.
5. Bozdag S., Gumus K., Gumus O., Unlu N. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis. Eur. J. Pharm. Biopharm. 2008, 70:260-269.
6. Calvo P., Vila-Jato J.L., Alonso M.J. Evaluation of cationic polymer-coated nancapsules as ocular drug carriers. Int. J. Pharm. 1997, 153:41-50.
7. Carney L.G., Fullard L.G. Ocular irritation and environmental pH. Aust. J. Optom. 1979, 62:335-336.
8. Chen X.D., Xin H., Ozkan N. Application of a depth sensing indentation hardness test to evaluate the mechanical properties of food materials. J. Food Sci. 2002, 67:1814-1820.
9. Chhabra R.P., Richardson J.F. Non-Newtonian Flow in the Process Industries 1999, Butterworth-Heinemann, Oxford.
10. Dalton K., Subbaraman L.N., Rogers R., Jones L. Physical properties of soft contact lense solutions. Optom. Vis. Sci. 2008, 85:122-128.
11. De la Fuente M., Ravina M., Paolicelli P., Sanchez A., Seijo B., Alonso M.J. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv. Drug Deliv. Rev. 2010, 62:100-117.
12. Dufier J.L. Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine. J. Pediatr. Ophthalmol. Strabismus 2003, 40:142-146.
13. Felt O., Baeyens V., Zignanai M., Buri P.A., Gurny R. Mucosal Drug Delivery-ocular. Encyclopedia of Controlled Drug Delivery 1999, vol. 2. University of Geneva, Geneva, Switzerland, pp. 605-622. 1st ed.
14. Fitzgerald P., Hadgraft J., Kreuter J., Wilson C.G. A γ-scintigraphic evaluation of microparticulate opthalmic delivery systems: liposomes and nanoparticles. Int. J. Pharm. 1987, 40:81-84.
15. Gahl W.A., Kuehl E.M. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol. Genet. Metab. 2000, 71:100-120.
16. Gangrade N.K., Gaddipati N.B., Ganesan M.G., Reddy I.K. Ocular Therapeutics and Drug Delivery 1996, Technomic Publishing, Lancaster. 1st ed.
17. Gunasekaran S., Mehmet A.K. Dynamic oscillatory shear testing of foods - selected applications. Trends Food Sci. Technol. 2000, 11:115-127.
18. Guo, J., 2007. Carbopol Polymers for Pharmaceutical Drug Delivery Applications. [online] Drug Delivery Technology, New Jersey. Available from: (accessed 01.12.09). http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=159.
19. Kay G., Cairns D., McCaughan B., Warasiha B. The design, synthesis and biological evaluation of novel prodrugs for the treatment of cystinosis. J. Pharm. Pharmacol. Suppl. 2007, 59:7.
20. Lang J.C. Ocular drug delivery - conventional ocular formulations. Adv. Drug. Deliv. Rev. 1995, 16:39-43.
21. Le Bourlais C., Acar L., Zia H., Sado P.A., Needham T., Leverge R. Ophthalmic drug delivery systems - recent advances. Prog. Retin. Eye Res. 1998, 17:33-58.
22. Levtchenko E., Besouw M., Blom H., Tangerman A., de Graaf-Hess A. The origin of halitosis in cystinotic patients due to cysteamine treatment. Mol. Genet. Metab. 2007, 91:228-233.
23. Llabot J.M., Palma S.D., Manzo R.H., Allemandi D.A. Design of novel antifungal mucoadhesive films: Part 1. Pre-formulation studies. Int. J. Pharm. 2007, 330:54-60.
24. McCaughan B., Kay G., Knott R.M., Cairns D. A potential new prodrug for the treatment of cystinosis: design, synthesis and in-vitro evaluation. Bioorg. Med. Chem. Lett. 2008, 18:1716.
25. Nanjawade B.K., Manvi F.V., Manjappa A.S. In situ forming hydrogels for sustained ophthalmic drug delivery. J. Control. Release 2007, 122:119-134.
26. Ooi E.H., Ng E.Y.K., Purslow C., Acharaya R. Variations in the corneal surface temperature with contact lens wear. J. Eng. Med. 2007, 3:94-500.
27. Park K., Robinson J.R. Mechanisms of mucoadhesion of poly (acrylic acid) and hydrogels. Pharm. Res. 1987, 4:457-464.
28. Pisoni R., Thoene J., Christtensen H. Detection and characterization of carrier mediated cationic amino acid transport in lysomsomes of normal and cystinotic fibroblasts, role in therapeutic cystine removal?. J. Biol. Chem. 1995, 260:4791-4798.
29. Robinson J.R. Ocular drug delivery mechanism(s) of corneal drug transport and mucoadhesive delivery systems. S.T.P. Pharm. 1989, 5:839-846.
30. Rossi S., Bonferoni M.C., Lippoli G., Bertoni M., Ferrari F., Caramella C., Conte U. Influence of mucin type on polymer-mucin rheological interactions. Biomaterials 1995, 16:1073-1079.
31. Rupenthal, I.D., 2008. Ocular delivery of antisense oligonucleotides using colloidal carriers: improving the wound repair after corneal surgery. Ph.D. Thesis, University of Aukland, New Zealand.
32. Salamat-Miller N., Chittchang M., Johnston T.P. The use of mucoadhesive polymers in buccal drug delivery. Adv. Drug Deliv. Rev. 2005, 57:1666-1691.
33. Schneider J.A. Treatment of cystinosis: simple in principle, difficult in practice. J. Pediatr. 2004, 145:436-438.
34. Schneider J.A., Fidler M.C., Barshop B.A., Deutsch R., Martin M., Dohil R. Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. Br. J. Clin. Pharmacol. 2006, 63:36-40.
35. Shell J.W. Ophthalmic drug delivery systems. Surv. Ophthalmol. 1984, 29:117-128.
36. Shotelersuk V., Larson D., Anikster Y., Mc Dowell G., Lemons R., Bernardini I., Guo J., Thoene J.G., Gahl W.A. CTNS mutations in an American-based population of cystinosis patients. Am. J. Hum. Genet. 1998, 63:1352-1362.
37. Slovin E.M., Robinson J.R. Bioadhesives in ocular drug delivery. Biopharmaceutics of Ocular Drug Delivery 1993, 145-157. CRC Press, Boca Raton, Florida. P. Edman (Ed.).
38. Tamburic S., Craig D.Q.M. The use of bioadhesive polymers as a means of improving drug delivery. Chemical Aspects of Drug Delivery Systems 1996, 11-40. Royal Society of Chemistry, London. 1st ed. D.R. Karsa, R.A. Stephenson (Eds.).
39. Thassu D., Deleers M., Pathak Y. Nanoparticulate drug delivery systems 2007, CRC Press, New York, USA. Illustrated ed.
40. Thoene J.G. A review of the role of enhanced apoptosis in the pathophysiology of cystinosis. Mol. Genet. Metab. 2007, 1-5.
41. Urtti A., Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. 1993, 37:435-456.